Project UpdateJun 16, 2026, 08:34 AM
Entera Bio Reports Positive Preclinical Data for EB612 & EB618
AI Summary
Entera Bio Ltd. reported positive preclinical data for its EB612 and EB618 pipeline programs at ENDO 2026. EB612, an oral peptide for hypoparathyroidism, demonstrated robust bioavailability and sustained calcium increases across three preclinical models, with an Investigational New Drug (IND) application expected in late 2026. EB618, an oral dual GLP-1/glucagon receptor agonist for obesity, showed dose-proportional pharmacokinetics and a strong effect on blood glucose in non-human primates. Both programs are co-developed with OPKO Health Inc.
Key Highlights
- EB612 restored serum calcium and reduced phosphate in TPTx rat model.
- EB612 showed sustained plasma levels for over three days in minipig model.
- EB612 produced a sustained serum calcium increase for approximately three days in non-human primates.
- EB612 Investigational New Drug (IND) application is expected in late 2026.
- EB618 exhibited dose-proportional systemic exposure across three tablet strengths.
- EB618 demonstrated a dose-proportional effect on postprandial blood glucose levels.
- Both EB612 and EB618 were well tolerated with no safety concerns identified.
Price Impact
More from ENTX